Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006249015> ?p ?o ?g. }
- W3006249015 endingPage "09" @default.
- W3006249015 startingPage "GS1" @default.
- W3006249015 abstract "Abstract BACKGROUND: Although long-term prognostic outcomes of primary breast cancer (PBC) patients have been improved remarkably in recent years, the disease recurrence remains a serious problem. We have previously investigated a role for oral fluoropyrimidines in postoperative adjuvant treatments.In this study, we aimed to verify the usefulness of S-1 in combination with adjuvant endocrine therapy for PBC patients having luminal disease. PATIENTS AND METHODS: This open-label, randomized, phase 3 trial was carried out in 139 centers in Japan. StageI-IIIPBC patients, who had hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negativestatus and intermediate or higher risk of recurrence were randomly assigned (1:1) to receive standard endocrine therapy alone (control arm) or endocrine therapy plus S-1 (S-1 arm). Recurrence risk assessment was performed using anatomical stage, pathological findings such as histologic grade, and centrally confirmed proliferative marker status. S-1 was administered postoperatively in combination with standard endocrine therapy. For patients who underwent multi-drug postoperative adjuvant or preoperative neoadjuvant chemotherapy, S-1 was administered following the multi-drug chemotherapy. Cases having no residual cancer in the breast and axillary node after the preoperative chemotherapy were excluded from this study. The S-1 dosage was chosen among 80 mg/day, 100 mg/day, and 120 mg/day according to the body surface area of each patient, and S-1 was administered for one year with a 2 weeks on/1 week off administration schedule. The primary endpoint was invasive disease-free survival (iDFS), defined as time from randomization to invasive disease recurrence, occurrence of second invasive cancer event, or death, and was analyzed on an intent-to-treat basis. Secondary endpoints included DFS, distant DFS, overall survival, and safety profile. RESULTS: From Feb 2012 to Feb 2016, 1959 patients were enrolled and 1932 patients were included in the full analysis set (control arm, 973; S-1 arm, 959). The results of the prespecified interim analysis met the primary end point, and this trial was terminated early. Median follow-up was 51.4 months. S-1 significantly reduced invasive events; 153 iDFS events were reported in the control arm and 99 iDFS events were reported in the S-1 arm [hazard ratio, 0.63 (95%CI, 0.49-0.81); p-value, 0.0003]. The 5-year iDFS estimate was 81.5% in the control arm and 86.9% in the S-1 arm. Distant recurrence as the first disease event was observed in 6.8% of patients in the S-1 arm and in 9.5% of those in the control arm. The safety data in patients treated with S-1 was consistent with the known profile of S-1. The S-1 treatment was well tolerated and manageable. CONCLUSIONS: It was concluded that the postoperative adjuvant use of an oralfluoropyrimidine S-1 significantly reduced iDFS events and improved 5-year iDFS estimate in PBC patients having HR-positive and HER2-negative disease, in the combination with standard endocrine therapy, with a feasible safety profile. Funding: This study was funded by the Comprehensive Support Project (CSP) of the Public Health Research Foundation. The research fund was provided to CSP by Taiho Pharmaceutical Co., Ltd. This trial was conducted as a study of ‘Advanced Medical Care,’ the Ministry of Health, Labour and Welfare, Japan. JRCT ID: jRCTs051180057, UMIN000003969 Citation Format: Masakazu Toi, Shigeru Imoto, Takanori Ishida, Yoshinori Ito, Hiroji Iwata, Norikazu Masuda, Hirofumi Mukai, Shigehira Saji, Akira Shimizu, Takafumi Ikeda, Hironori Haga, Toshiaki Saeki, Kenjiro Aogi, Tomoharu Sugie, Takayuki Ueno, Takayuki Kinoshita, Yuichiro Kai, Masahiro Kitada, Yasuyuki Sato, Kenjiro Jimbo, Nobuaki Sato, Hiroshi Ishiguro, Masahiro Takada, Yasuo Ohashi, Shinji Ohno. Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr GS1-09." @default.
- W3006249015 created "2020-02-24" @default.
- W3006249015 creator A5001364171 @default.
- W3006249015 creator A5002212423 @default.
- W3006249015 creator A5005805045 @default.
- W3006249015 creator A5008549101 @default.
- W3006249015 creator A5015330532 @default.
- W3006249015 creator A5021782707 @default.
- W3006249015 creator A5026753786 @default.
- W3006249015 creator A5034292099 @default.
- W3006249015 creator A5034349158 @default.
- W3006249015 creator A5036168618 @default.
- W3006249015 creator A5038484790 @default.
- W3006249015 creator A5044707802 @default.
- W3006249015 creator A5045663914 @default.
- W3006249015 creator A5054182730 @default.
- W3006249015 creator A5056628460 @default.
- W3006249015 creator A5060702089 @default.
- W3006249015 creator A5061220478 @default.
- W3006249015 creator A5067189124 @default.
- W3006249015 creator A5067693447 @default.
- W3006249015 creator A5072529427 @default.
- W3006249015 creator A5075853905 @default.
- W3006249015 creator A5077292819 @default.
- W3006249015 creator A5081166185 @default.
- W3006249015 creator A5089829213 @default.
- W3006249015 creator A5090955736 @default.
- W3006249015 date "2020-02-15" @default.
- W3006249015 modified "2023-10-15" @default.
- W3006249015 title "Abstract GS1-09: Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial)" @default.
- W3006249015 doi "https://doi.org/10.1158/1538-7445.sabcs19-gs1-09" @default.
- W3006249015 hasPublicationYear "2020" @default.
- W3006249015 type Work @default.
- W3006249015 sameAs 3006249015 @default.
- W3006249015 citedByCount "1" @default.
- W3006249015 countsByYear W30062490152020 @default.
- W3006249015 crossrefType "journal-article" @default.
- W3006249015 hasAuthorship W3006249015A5001364171 @default.
- W3006249015 hasAuthorship W3006249015A5002212423 @default.
- W3006249015 hasAuthorship W3006249015A5005805045 @default.
- W3006249015 hasAuthorship W3006249015A5008549101 @default.
- W3006249015 hasAuthorship W3006249015A5015330532 @default.
- W3006249015 hasAuthorship W3006249015A5021782707 @default.
- W3006249015 hasAuthorship W3006249015A5026753786 @default.
- W3006249015 hasAuthorship W3006249015A5034292099 @default.
- W3006249015 hasAuthorship W3006249015A5034349158 @default.
- W3006249015 hasAuthorship W3006249015A5036168618 @default.
- W3006249015 hasAuthorship W3006249015A5038484790 @default.
- W3006249015 hasAuthorship W3006249015A5044707802 @default.
- W3006249015 hasAuthorship W3006249015A5045663914 @default.
- W3006249015 hasAuthorship W3006249015A5054182730 @default.
- W3006249015 hasAuthorship W3006249015A5056628460 @default.
- W3006249015 hasAuthorship W3006249015A5060702089 @default.
- W3006249015 hasAuthorship W3006249015A5061220478 @default.
- W3006249015 hasAuthorship W3006249015A5067189124 @default.
- W3006249015 hasAuthorship W3006249015A5067693447 @default.
- W3006249015 hasAuthorship W3006249015A5072529427 @default.
- W3006249015 hasAuthorship W3006249015A5075853905 @default.
- W3006249015 hasAuthorship W3006249015A5077292819 @default.
- W3006249015 hasAuthorship W3006249015A5081166185 @default.
- W3006249015 hasAuthorship W3006249015A5089829213 @default.
- W3006249015 hasAuthorship W3006249015A5090955736 @default.
- W3006249015 hasConcept C121608353 @default.
- W3006249015 hasConcept C126322002 @default.
- W3006249015 hasConcept C141071460 @default.
- W3006249015 hasConcept C143998085 @default.
- W3006249015 hasConcept C168563851 @default.
- W3006249015 hasConcept C203092338 @default.
- W3006249015 hasConcept C2776694085 @default.
- W3006249015 hasConcept C2777982462 @default.
- W3006249015 hasConcept C2778311097 @default.
- W3006249015 hasConcept C46699223 @default.
- W3006249015 hasConcept C530470458 @default.
- W3006249015 hasConcept C71315377 @default.
- W3006249015 hasConcept C71924100 @default.
- W3006249015 hasConceptScore W3006249015C121608353 @default.
- W3006249015 hasConceptScore W3006249015C126322002 @default.
- W3006249015 hasConceptScore W3006249015C141071460 @default.
- W3006249015 hasConceptScore W3006249015C143998085 @default.
- W3006249015 hasConceptScore W3006249015C168563851 @default.
- W3006249015 hasConceptScore W3006249015C203092338 @default.
- W3006249015 hasConceptScore W3006249015C2776694085 @default.
- W3006249015 hasConceptScore W3006249015C2777982462 @default.
- W3006249015 hasConceptScore W3006249015C2778311097 @default.
- W3006249015 hasConceptScore W3006249015C46699223 @default.
- W3006249015 hasConceptScore W3006249015C530470458 @default.
- W3006249015 hasConceptScore W3006249015C71315377 @default.
- W3006249015 hasConceptScore W3006249015C71924100 @default.
- W3006249015 hasIssue "4_Supplement" @default.
- W3006249015 hasLocation W30062490151 @default.
- W3006249015 hasOpenAccess W3006249015 @default.
- W3006249015 hasPrimaryLocation W30062490151 @default.
- W3006249015 hasRelatedWork W1735392790 @default.
- W3006249015 hasRelatedWork W1991307975 @default.
- W3006249015 hasRelatedWork W1992557798 @default.
- W3006249015 hasRelatedWork W2172254302 @default.
- W3006249015 hasRelatedWork W2354425668 @default.
- W3006249015 hasRelatedWork W2429402395 @default.